Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2017 Mar 01





Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236



Minerva Medica 2017 Mar 01

DOI: 10.23736/S0026-4806.17.04807-8


lingua: Inglese

Serum Dickkopf-1 act as a new biomarker in human breast cancer

Jin-Tao LIU , Wen-Bin GUO, Jia-Yi SUN

Department of Breast Surgery, The Central Hospital of Dalian, Dalian, Liaoning Province, China


BACKGROUND: The serum levels of Dickkopf-1 (Dkk1), a secreted Wnt family protein is changed in patients suffering various types of cancers. In the present study, we aim to explore the diagnostic value of Dkk1 as a new biomarker in breast cancer.
METHODS: Serum was collected from 38 patients with breast cancer and 23 healthy controls. Serological levels of DKK1 were examined by enzyme-linked immunosorbent assay (ELISA). Significance and diagnostic performance including receiver operator characteristic (ROC) and areas under the curve (AUC) were determined by SPSS software.
RESULTS: Serum level of Dkk1 was significantly increased in breast cancer patients compared to the healthy controls (P˂0.05). The expression levels of CA15-3 were also evaluated in patients suffering from breast cancer in comparison with healthy controls (P˂0.05). AUC for Dkk1 and CA15-3 were 0.81 and 0.64 respectively. Sensitivity and specificity of Dkk1 were more than CA15-3 in earlier stage of breast cancer. Dkk1 expression in HER-2, ER and PR positive patients was decreased compared with HER-2, ER and PR negative patients.
CONCLUSIONS: We found that the expression level of Dkk1 in serum was increased in breast cancer patients, suggesting that serum expression level of Dkk1 could be a useful biomarker in breast cancer.

KEY WORDS: Breast cancer - Dkk1 - CA15-3 - ROC - AUC

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail